ClinicalTrials.gg
CompletedNCT05180565SAFE2019Updated May 1, 2026

Safe Anastomosis Feasibility Study

An interventional study of Colovac in Colorectal Cancer and Anastomosis, sponsored by SafeHeal Inc. Completed at 7 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-01.

Sponsored by SafeHeal Inc · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 10 months after the study started (first participant enrolled Dec 2019, registered Oct 2021).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
27
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 583 studies in Colorectal Neoplasms with a site in France — 111 open to participants now, 165 under way, 26 of them phase 3. Colorectal Neoplasms · France.

Enrollment
405th of 464
27 · median 152
Started
2019
with 37 others
No phase
116 of 583
25 open now
Registered
431st of 583
by date

Among the 583 studies in Colorectal Neoplasms with a site in France, this one is the 405th largest by enrollment of the 464 interventional ones that give a count, is one of 38 that started in 2019, is one of 116 with no phase, and was the 431st registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

111 of the 583 studies in Colorectal Neoplasms with a site in France are open now. Recruiting first, the newest first:

106 more — sign in →

All 111 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 583 studies in Colorectal Neoplasms with a site in France, or all of them as a file.
02

Study summary

A clinical trial to assess the efficacy, mechanism of action and safety of the Colovac+ Colorectal Anastomosis Protection Device in providing temporary protection of the anastomosis in subjects undergoing lower anterior resection for colorectal cancer

Read the detailed description

A primary diverting stoma is widely used by surgeons in order to bypass the low rectal anastomosis and reduce morbidity associated with anastomotic leaks. Typically, a stoma is created for all high-risk patients which means that many patients are exposed to potentially serious complications associated with the stoma itself without any clinical benefit.

Colovac+ is a local, temporary, minimally invasive bypass device that provides protection of the anastomosis and safely postpones stoma creation for 10 days after surgery. By postponing stoma creation for 10 days, Colovac is designed to avoid stoma creation in all patients except those patients whose anastomoses have not healed by 10 days after surgery, allowing the others to return to normal activity more quickly and safely.

03

Conditions studied

  • Colorectal Cancer
  • Anastomosis

Keywords

  • anastomosis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients (18 years of age or older)
  • Eligible to undergo open or minimally invasive sphincter-sparing low anterior resection with planned diverting loop ileostomy for , based on multidisciplinary team recommendations.
  • Willingness to comply with Clinical Investigation Plan-specific treatment and study visits and to sign a written Form

Exclusion criteria

Exclusion Criteria:

- Preoperatively :

  1. Patient with inflammatory bowel disease
  2. Known allergy to nickel or other components of the Colovac+ kit
  3. Pregnant or nursing female subject
  4. Concomitant major surgical procedure in combination with Colorectal resection (i.e. hepatectomy)
  5. Any serious or uncontrolled medical disorder that, in the opinion of the investigator, may increase the risk associated with study participation, impair the ability of the participant to undergo Clinical Investigation Plan described procedures or interfere with the interpretation of study results. including, but not limited to:

    1. COVID-19 positive (active infection) based on test within 72 hours prior to surgery
    2. disease - unless previously treated with chemotherapy and resection, and the benefit of exposure to the Colovac device is greater than the risk 1
    3. Immunodeficiency ( \< 500 CU MM)
    4. Systemic therapy within the past 6 months
    5. Systemic infection at the time of surgery or requiring systemic antimicrobial therapy up to 1 week before surgery
    6. Major surgical or interventional procedures within 30 days prior to this study or planned surgical or interventional procedures within 30 days of entry into this study
    7. Diagnosis of bowel obstruction, bowel strangulation, peritonitis, bowel perforation, intraabdominal infection, ischemic bowel, carcinomatosis
    8. Fecal incontinence, involvement of sphincter by the neoplastic disease or evidence of extensive local disease in the pelvis seen on pre-operative imaging
    9. Severe Malnutrition defined as 10% weight loss within 3 months prior to enrollment.
  6. The subject is currently participating in another drug or device study

    • Intraoperatively :
  7. Anastomosis placement at more than 10cm from anal margin
  8. Occurrence of any of the following during the colorectal surgery:

    1. Blood loss (>750 cc)
    2. Blood transfusion
    3. Any new sign of ischemia
    4. Positive air leak test - requiring re intervention on the anastomosis
    5. Inadequate bowel preparation
    6. Other intra-operative risks that preclude the subject from undergoing the procedure with the investigational device
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
27 participants (actual)

Study arms

  • Experimental
    Colovac

    Patients receive Colovac device during colorectal surgery

    Device: Colovac

Interventions

  • DeviceColovac

    A removable, temporary intraluminal bypass device designed to safely postpone the creation of a protective stoma until 10 days after surgery for only patients who need it (do not have a healed anastomosis)

06

What researchers measure

Primary outcomes

  1. To measure the incidence of serious adverse events related to using the device

    The primary endpoint will be a measurement of SAEs probably related or causaly related to the use of the investigational device, to the index surgery in this clinical trial.

    Time frame: 3 months

Secondary outcomes

  1. To measure the number of participants with evidence of absence of feces between the sheath and the colonic wall before device retrieval

    Rate of patients with evidence of absence of feces between the sheath and the colonic wall before device retrieval at 10 days:

    Time frame: 10 days

  2. To measure the rate of ostomy avoidance

    To measure the number of participants where ostomy was avoided

    Time frame: 3 months

  3. To evaluate the occurrence of clinical anastomotic leakage

    Rate of clinical leakage, defined as number of clinically manifest insufficiency of the anastomosis leading to a clinical state requiring treatment: * Rate of patients with radiological evidence of anastomotic leakage if the patient is clinically symptomatic * Prior to retrieval of the Colovac+ Device, a systematic contrast radiographic imaging will be performed using a radio-opaque contrast agent injected trans-anally, in order to check for any potential anastomotic complication.

    Time frame: 3 months

  4. To measure on a scale of 1 to 5 rated by the surgeon the ease of device introduction, positioning and endoscopic retrieval

    * Ease of device introduction and positioning will be rated by the surgeon on a scale from 1 to 5 (1 being very easy and 5 being impossible) * Ease of endoscopic retrieval of the device will be rated by the endoscopist on a scale from 1 to 5 (1 being very easy and 5 being impossible)

    Time frame: 10 days

  5. To evaluate the clinically significant migration rate

    Clinically significant migration is defined as movement of device that allows fecal contents to reach the anastomosis site evidenced by: * Migration of entire stent to or below the Sacral Promontory as indicated by fluctuation in the length of the sheath that extends out of the anus and confirmed by radiographicdisplacement; or * Expulsion of the device

    Time frame: 10 days

  6. To evaluate the integrity above the anchoring site during the device retrieval using endoscopy.

    Mucosal appearance above the anchoring site will be evaluated endoscopically during device retrieval and classified as Normal/Inflamed, Bleeding, Ulcerated, Perforated.

    Time frame: 10 days

  7. To evaluate the integrity of the anchoring site during the device retrieval using endoscopy.

    Mucosal appearance at the anchoring site will be evaluated endoscopically during device retrieval and classified as Normal/Inflamed, Bleeding, Ulcerated, Perforated.

    Time frame: 10 days

  8. To evaluate the integrity of the anastomosis before the device retrieval using fluoroscopy

    Fluoroscopy with injection of contrast between the colonic wall and the sheath will be performed prior to retrieval of the Colovac+ Device in order to check for anastomotic integrity before device retrieval. Outcome is measured with presence/absence of any contrast liquid leak through the anastomosis prior to device retrieval.

    Time frame: 10 days

  9. To evaluate the integrity of the anastomosis after the device retrieval using fluoroscopy

    Fluoroscopy with injection of contrast per rectum will be performed immediately after retrieval of the Colovac+ Device in order to check for anastomotic integrity following device retrieval. Outcome is measured with presence/absence of any contrast liquid leak through the anastomosis after device retrieval.

    Time frame: 10 days

  10. To measure the average procedure time

    The average procedure time at the day of implantation

    Time frame: 1 day

  11. To measure the patient tolerability of the device using a patient questionnaire

    Responses to a patient questionnaire on device acceptance, on the device handling and comfort, and on preference compared to an ostomy - utilizing the NIH's (National Institute of Health) PROMIS (Patient-Reported Outcomes Measurement Information System) health measurement questionnaires to assess parameters like pain, bowel incontinence, constipation, diarrhea, or anxiety and social isolation, on a scale from 1 to 10 (1 being absence of difficulty and 10 being severe problems).

    Time frame: 10 days

07

Study locations

7 sites
  • UZA
    Antwerp, 2610, Belgium
  • Centre Hospitalier Universitaire St Pierre
    Brussels, 1000, Belgium
  • CHU Lille
    Lille, 59000, France
  • ICM Montpellier
    Montpellier, 34090, France
  • Hôpital Saint Louis
    Paris, 75010, France
  • Hôpital Saint Antoine Paris
    Paris, 75012, France
  • CHRU Strasbourg
    Strasbourg, 67000, France
08

References and documents

Publications

  • De Hous N, D'Urso A, Cadiere GB, Cadiere B, Rouanet P, Komen N, Lefevre JH. Evaluation of the SafeHeal Colovac+ anastomosis protection device after low anterior resection for rectal cancer: the safe anastomosis feasibility evaluation (SAFE) 2019 trial. Surg Endosc. 2023 Sep;37(9):7385-7392. doi: 10.1007/s00464-023-10272-x. Epub 2023 Jul 18. PubMed 37464064 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2019 to primary completion in Feb 2022, 26 months.

Of 58 industry-sponsored interventional studies with no phase under Colorectal Neoplasms, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 37. This study's 26 months is above that.

Counting every sponsor, half of 958 studies reached it within 31 months; a quarter within 14 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2021
First posted
Jan 6, 2022
StartActual
Dec 18, 2019
Primary completionActual
Feb 28, 2022
CompletionActual
Mar 31, 2022
Last update
May 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05180565
Lead sponsor
SafeHeal Inc
Responsible party
Sponsor
First posted
Jan 6, 2022
Start date
Dec 18, 2019
Primary completion
Feb 28, 2022
Completion
Mar 31, 2022
Last update
May 1, 2026

Study contacts

Jérémie Lefevre
principal investigator · Hôpital Saint Antoine Paris

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion